Liminal BioSciences Inc. PFSCF

RE:FDA green light on riplazym next weeks...

[stockbuphoon]

realstocky/Newcamo (same guy), you forgot this piece exactly from the results call: 
 

• Liminal mgmt said clearly in call that they had not completed plant inspection in Laval due to covid restrictions and they said this in press release...
• We anticipate implementing strategic alternative(s) for the plasma-derived therapeutics business in 2021, these alternatives may result in a divestment, in whole or in part, of the plasma-derived therapeutics business and/or other non-core assets, or in other courses of action including but not limited to other strategic transactions or the closure of the Ryplazim® related operations,to focus use of cash on our small molecule therapeutics business;

realstocky wrote: conference call days ago: " I think it's without giving anything away on what we're doing with negotiations and discussions that would be commercially sensitive. The reality is that we are looking at all opportunities here, whether we do this before or after Ryplazim approval. "<<<< =================

 

incoming........$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$

=================================================================

 

confirmed as well on latest NR

PDUFA target action date of June 5, 2021 for Ryplazim

"2021 has the potential to be a transformative one for Liminal BioSciences as we progress our evaluation of strategic alternatives for our plasma-derived therapeutics business, while continuing to work towards the PDUFA target action date of June 5, 2021 for Ryplazim ® (plasminogen)," stated Patrick Sartore , President of Liminal BioSciences.
+++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++

 yes, riplazym on its way to be partnered before or after APPROVAL. (conference call  days ago).

======================================================================

 

LMNL Analyst Ratings

Consensus Buy

Based on 3 analysts offering recommendations for lmnl in the last 3 months.

Analyst Firms Making Recommendations

• BLOOM BURTON&CO
• ECHELON WEALTH
• PIPER SANDLER

Analyst

$22

 

https://www.nasdaq.com/market-activity/stocks/lmnl/analyst-research